A new preclinical study published in Cancer Research has identified a possible way to attack prostate cancer that has become resistant to castration and enzalutamide. The work focuses on BUB1B, a protein involved in controlling cell division, and CENP-E, one of the proteins it helps regulate. When researchers lowered BUB1B levels, resistant prostate cancer cells […]
An inexpensive antifungal drug that has been used for decades is now being tested as a prostate cancer treatment. The phase 2 TerbinaPro trial is evaluating terbinafine in men whose prostate cancer has returned biochemically after previous treatment. Behind this unusual drug-repurposing trial lies an intriguing discovery about how prostate cancer produces cholesterol. The target […]
LAST WEEK TODAY! A summary of what was published on ProstateWarriors.com during the past week Hello fellow warriors! Summer is over, research publishing has picked up again, and this week we have plenty of interesting information to read! Stay strong and fight on! As usual, we also have a podcast if you prefer to listen to the […]
Prostate cancer that develops neuroendocrine features is commonly associated with loss of androgen-receptor dependence and reduced PSMA expression, potentially making PSMA-targeted treatments less useful. A new dual-tracer imaging study suggests that the reality may be considerably more complicated. Researchers retrospectively examined eight men with metastatic castration-resistant prostate cancer who were suspected of developing treatment-emergent neuroendocrine […]
A new retrospective study with a 10-year follow-up suggests that some men with prostate cancer recurring only in lymph nodes may achieve prolonged disease control using PET-directed radiotherapy combined with temporary androgen deprivation therapy (ADT). The retrospective study included 93 men with hormone-sensitive prostate cancer that had returned in pelvic and/or para-aortic lymph nodes after […]
A next-generation PARP inhibitor called SNV1521 is showing early signs of activity in advanced prostate cancer, while potentially causing less bone-marrow toxicity than existing PARP drugs. SNV1521 is an oral drug designed to selectively inhibit PARP1 while largely sparing PARP2. Current PARP inhibitors such as olaparib inhibit both proteins, and suppression of PARP2 is thought […]
A new analysis of the PRINCE clinical trial suggests that combining blood-based ctDNA testing with PSMA PET could help identify which men with metastatic castration-resistant prostate cancer (mCRPC) are most likely to respond to Lu-177 PSMA plus immunotherapy. PRINCE was a multicentre Phase 1/2 trial involving 37 men with mCRPC. Patients received up to six […]
A blood test taken before starting treatment could help identify men with metastatic hormone-sensitive prostate cancer (mHSPC) who are at greater risk of developing treatment resistance early. We have already discussed the importance of ctDNA after treatment in a previous article, but this new study looks at its potential value even before treatment begins. A […]
A new prospective clinical study suggests that radium-223 may change the immune environment of prostate cancer bone metastases in a way that makes subsequent immunotherapy less effective. The study included 28 men with metastatic castration-resistant prostate cancer (mCRPC) and predominantly bone metastases. Patients received radium-223, with six injections planned at four-week intervals. Researchers wanted to […]
A simple blood test normally associated with colorectal cancer could provide additional information about how men with metastatic castration-resistant prostate cancer fare after 177Lu-PSMA-617 therapy. A new prospective study of 142 patients found that elevated carcinoembryonic antigen (CEA) before treatment was independently associated with shorter progression-free and overall survival. The finding does not mean that […]